Evidence Trace, complete trial record

In plain terms

In plain terms: Photobiomodulation to Prevent Oral Mucositis has strong evidence from human clinical trials. The benefit shown in those trials is if that describes your situation.

Photobiomodulation to Prevent Oral Mucositis

A Replicated: replicated trials on a qualifying endpoint

Category Devices

Evidence Randomized controlled trials + meta-analysis of randomized trials

Reviewed September 2026

PMIDs 24044799 · 22884841 · 22502814 · 26248655 · 20969443 · 17393191 · 42360517 · 38265122 · 36935333 · 31286228 · 31118057 · 16862549 · 38688628 · 39294629

The endpoint this grade is based on: Validated scale scored by a clinician blinded to treatment

The evidence as the record states it

Evidence record

PMID 24044799 PMID 22884841 PMID 22502814 PMID 26248655 PMID 20969443 PMID 17393191 PMID 42360517 PMID 38265122 PMID 36935333 PMID 31286228 PMID 31118057 PMID 16862549 PMID 38688628 PMID 39294629

Antunes et al. (Radiother Oncol, 2013; PMID 24044799): 94 patients on chemoradiation for head and neck cancer, double-blind placebo-controlled; grade 3 to 4 mucositis 6.4% versus 40.5%. Gautam et al. (Radiother Oncol, 2012; PMID 22884841): 221 patients, triple-blind sham; severe mucositis, swallowing pain and opioid use all reduced. Gautam et al. (Oral Oncol, 2012; PMID 22502814): 121 patients; severe mucositis 29% versus 89%, treatment breaks 0% versus 9%. Ferreira et al. (Support Care Cancer, 2016; PMID 26248655): 35 stem cell transplant patients; severe mucositis 17.6% versus 61.1%. Silva et al. (Photomed Laser Surg, 2011; PMID 20969443): 42 transplant patients. Schubert et al. (Support Care Cancer, 2007; PMID 17393191): 70 transplant patients; 650 nm reduced severity, 780 nm did not. Hu et al. (Support Care Cancer, 2026; PMID 42360517): 85 patients at 12 US sites, intraoral LED device, double-blind sham; grade 3 or higher 36.8% versus 57.1%. Shen et al. (Head Neck, 2024; PMID 38265122): meta-analysis of 14 trials, 869 patients; severe mucositis risk ratio 0.45. Chan et al. (Semin Oncol Nurs, 2023; PMID 36935333): transplant meta-analysis, 18 trials. Zadik et al. (Support Care Cancer, 2019; PMID 31286228): MASCC/ISOO guideline recommending prevention protocols. Kept in the record: Legoute et al. (Radiat Oncol, 2019; PMID 31118057), treatment of established sores rather than prevention, no difference; Cruz et al. (Pediatr Blood Cancer, 2007; PMID 16862549) and Andriakopoulou et al. (In Vivo, 2024; PMID 38688628), no benefit in children; Rodrigues et al. (BMC Oral Health, 2024; PMID 39294629), most systematic reviews in this field rated critically low quality.

PMID 24044799 PMID 22884841 PMID 22502814 PMID 26248655 PMID 20969443 PMID 17393191 PMID 42360517 PMID 38265122 PMID 36935333 PMID 31286228 PMID 31118057 PMID 16862549 PMID 38688628 PMID 39294629

Why Grade A and not higher

Grade A requires a hard clinical endpoint or objectively measured functional outcome, independently replicated across at least two trials. Photobiomodulation to Prevent Oral Mucositis meets that standard based on the trials cited above. A downgrade to Grade B would follow if replication attempts produced null results, if the effect size proved substantially smaller in a broader population, or if the studied dose proved impractical to sustain.

What this grade covers and what it does not

Grade A under the rule as revised in September 2026, which counts a validated outcome scale scored by a clinician blinded to treatment. The mucositis grade is assigned by a clinician examining the mouth, and its top grades are partly functional: grade 3 means only liquids can be swallowed, grade 4 means nothing by mouth. Across sham-controlled trials from independent groups in Brazil, India and the United States, severe mucositis fell by roughly half or more, supported by fewer opioids and fewer treatment breaks, and the international MASCC/ISOO guideline recommends it for prevention. WHAT THIS GRADE DOES NOT COVER: treating sores that have already formed (a phase III trial of treatment found no difference); children, where trials and a pooled analysis found no benefit; and chemotherapy alone outside transplant. Feeding tube use was not reduced significantly in the two trials that measured it. Heterogeneity between trials is high, the largest trials come from one group in India, and most systematic reviews in this field are rated low quality. No device is FDA-cleared for this use in the United States.

What would move this grade

A null result in a well-powered independent replication trial, or evidence that the effect does not hold at a practically sustainable dose, would prompt downgrade to Grade B.

How this was studied

Form: Low-level laser or LED light, red (about 630 to 660 nm) or near-infrared, applied intraorally to the mucosa by trained staff · Dose: Protocol-specific energy per point as set out in the MASCC/ISOO guideline; typically daily or 5 days a week · Population: Adults receiving head and neck radiotherapy or chemoradiation, or undergoing hematopoietic stem cell transplant · Duration: Started with cancer treatment and continued through the course of radiotherapy or conditioning · What is sold differs: Home red-light devices are sold for mouth sores; this grade describes clinician-applied prevention protocols during cancer treatment only.

How to track whether this is working Oral mucositis grade (WHO or NCI scale) assessed by the treating team at each visit through the course of radiotherapy or transplant, plus opioid use, feeding tube placement and unplanned treatment breaks.